Factors in Selecting First-Line Therapy for Patients With Advanced RCC

Video

Comprehensive insight on the factors that help determine optimal first-line therapy for a patient presenting with advanced renal cell carcinoma.

CN-RCC-FF-CampRini-Seg02
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
      Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
      Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
      Incentivizing RCC Research Investment Across Lower-Income Countries
      Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
      Identifying Regional Kidney Cancer Needs Via International Collaboration
      Future of HER2-Directed Tumor-Agnostic Therapies
      Future of HER2-Directed Tumor-Agnostic Therapies
      Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
      Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
      Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
      Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
      Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
      Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
      HER2 Key Differences and Current Approaches to Biomarker Testing
      HER2 Key Differences and Current Approaches to Biomarker Testing
      Introduction to HER2-Directed Tumor-Agnostic Approaches
      Introduction to HER2-Directed Tumor-Agnostic Approaches
      Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
      Using Biopsies to Inform Response Characteristics in Kidney Cancer
      Related Content
      Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.

      Belzutifan Improves Disease-Specific Symptoms/QOL vs Everolimus in RCC

      Roman Fabbricatore
      April 6th 2025
      Article

      Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.

      Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

      Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
      April 1st 2025
      Podcast

      A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

      Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.

      FDA Grants Priority Review to TLX250-CDx in Clear Cell RCC Imaging

      Russ Conroy
      February 26th 2025
      Article

      Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.

      Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

      Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
      March 7th 2025
      Podcast

      A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

      LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

      Belzutifan Receives European Approval in Localized/Advanced RCC Indications

      Roman Fabbricatore
      February 18th 2025
      Article

      LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

      PROs Comparable with Tivozanib Alone or With Nivolumab in Advanced Clear Cell RCC

      PROs Comparable with Tivozanib Alone or With Nivolumab in Advanced Clear Cell RCC

      Ashley Chan
      February 16th 2025
      Article

      The TiNivo-2 trial found comparable PROs with tivozanib plus nivolumab vs tivozanib monotherapy in advanced clear cell RCC.